Upadhyaya Santhosh A, Mody Rajen, Walkovich Kelly, Hutchinson Raymond J, Sandlund John T, Connelly James A
Department of Oncology, St. Jude Children's Research Hospital.
Department of Pediatrics and Communicable Diseases, Division of Pediatric Hematology Oncology, University of Michigan Medical School, Ann Arbor, MI.
J Pediatr Hematol Oncol. 2018 Aug;40(6):483-486. doi: 10.1097/MPH.0000000000001005.
Immune dysregulation and predisposition to malignancies are critical comorbidities in children affected with ataxia telangiectasia. In addition, these children exhibit increased toxicity to conventional cancer therapy and dose reductions have been proposed to prevent life threatening adverse effects. These modifications to the treatment regimen may result in suboptimal outcomes for these patients. Our report of 3 children with ataxia telangiectasia and cancer highlight the immense challenges in the management of these children, underlining the need for the development of novel, biological agents with reduced acute and long-term side effects in the treatment of cancers in these children.
免疫失调和易患恶性肿瘤是患有共济失调毛细血管扩张症儿童的关键合并症。此外，这些儿童对传统癌症治疗的毒性增加，有人提议减少剂量以预防危及生命的不良反应。治疗方案的这些调整可能导致这些患者的治疗效果欠佳。我们关于3例患有共济失调毛细血管扩张症和癌症儿童的报告凸显了管理这些儿童的巨大挑战，强调需要开发新型生物制剂，以减少这些儿童癌症治疗中的急性和长期副作用。
